News

Blog Events News

Yposkesi reinforces team with three executive appointments

Corrie Hulten

Yposkesi appoints US-based Executive Director for Business Development

Logos Asma Consortium

ASMA Consortium: Improving access to innovative bio therapeutics through acoustic technologies

22 February 2022

New Yposkesi factory

Yposkesi launches construction of its second bioproduction site.

Yposkesi front office

Yposkesi welcomes SK Group as new majority equity shareholder, forging solid industrial partnership for growth.

Yposkesi front office

Apres le Génopole, Novartis choisit l’Essonne pour ses therapies géniques

9 December 2020

Brian Mullan

Yposkesi welcomes Brian Mullan, PhD, as director of innovation, analytical and process development

8 December 2020

Patrick Lansky

Yposkesi welcomes Patrick Lansky as VP of US sales & marketing

Yposkesi’s clinical batches of G1XCGD lentiviral vector used in rare immune system disease study

30 January 2020

Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program

24 January 2020

Would you like to know more ?